GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
GlycoMimetics, Inc. (NASDAQ: GLYC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
INVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYC